🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of Preoperative CIMT on Hemodynamics During Liver Transplantation

Recruitingn/aAges 18 Years - anyAllDicle University
NCT07660679 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Candidates for liver transplantation (CT) carry an increased risk of cardiovascular disease (CVD) due to underlying end-stage liver disease (ESHD) and immunosuppressive drugs used post-transplantation. CVD is a significant cause of long-term mortality after CT \[1\] \[2\]. Carotid Intima-Media Thickness (CIMT), a subclinical marker of atherosclerosis in the preoperative period, is a non-invasive method used to predict future CVD risk \[3\]. High CIMT indicates atherosclerosis and decreased arterial compliance. This can compromise organ perfusion and increase the risk of postoperative complications by increasing intraoperative blood pressure variability (BPV) during anesthesia induction and surgical stress in major surgeries such as CT. Studies investigating whether CIMT is an independent risk factor for perioperative hemodynamic instability in CT patients are limited. The aim of our stud

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged between 18 and 65 years * Scheduled for elective liver transplantation surgery * Completed preoperative carotid intima-media thickness (CIMT) ultrasonographic measurement * Patients with signed informed consent for data collection Exclusion Criteria: * Patients undergoing emergency liver transplantation * History of previous carotid artery surgery or stenting * Known severe carotid artery stenosis (\>70%) * Severe intraoperative hemodynamic instability prior to induction (e.g., active bleeding or shock) * Incomplete intraoperative advanced hemodynamic monitoring data or vasopressor records
💊

What it tests

  • Not listed
📍

Where

1 site
Dicle University Faculty of Medicine, Department of Anesthesiology and Reanimation
Diyarbakır, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy